Guangdong Hybribio Biotech Co.,Ltd. (SHE:300639)
China · Delayed Price · Currency is CNY 6.14
+0.22 (3.72%)
Sep 1, 2026, 3:04 PM CST
SHE:300639 Revenue
Guangdong Hybribio Biotech had revenue of 174.24M CNY in the quarter ending June 30, 2026, a decrease of -3.70%. This brings the company's revenue in the last twelve months to 654.72M, down -9.27% year-over-year. In the year 2025, Guangdong Hybribio Biotech had annual revenue of 669.64M, down -17.89%.
Revenue (ttm)
654.72M
Revenue Growth
-9.27%
P/S Ratio
5.68
Revenue / Employee
329.00K
Employees
1,990
Market Cap
3.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 669.64M | -145.89M | -17.89% |
| Dec 31, 2024 | 815.53M | -288.93M | -26.16% |
| Dec 31, 2023 | 1.10B | -4.49B | -80.27% |
| Jan 1, 2023 | 5.60B | 2.92B | 109.39% |
| Jan 1, 2022 | 2.67B | 1.32B | 97.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Runda Medical Technology | 6.72B |
| Maccura Biotechnology Co.Ltd | 2.13B |
| Medicalsystem Biotechnology | 1.63B |
| Beijing Strong Biotechnologies,Inc. | 1.37B |
| Shanghai Labway Clinical Laboratory | 1.28B |
| Amoy Diagnostics | 1.18B |
| Berry Genomics Co.,Ltd | 929.15M |
| Thalys Medical Technology Group | 836.23M |